<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182020000100137</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v49n1.87030</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perfil de uso de anticoagulantes en pacientes hospitalizados, interacciones farmacológicas y reacciones adversas identificadas]]></article-title>
<article-title xml:lang="en"><![CDATA[Anticoagulant use profile in hospitalized patients, drug interactions and identified adverse reactions]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejos Narváez]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bello Benavides]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez Salgado]]></surname>
<given-names><![CDATA[María del Mar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuervo Medina]]></surname>
<given-names><![CDATA[Marcia Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fajardo Granados]]></surname>
<given-names><![CDATA[David Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiroga Luque]]></surname>
<given-names><![CDATA[Clara Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zhong Lin]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arévalo Pereira]]></surname>
<given-names><![CDATA[Kenndy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buitrago González]]></surname>
<given-names><![CDATA[Tatiana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[María Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Universitaria de Ciencias de la Salud (FUCS)  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universitaria de Ciencias de la Salud, (FUCS)  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Universitaria de Ciencias de la Salud (FUCS)  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad del Rosario Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>49</volume>
<numero>1</numero>
<fpage>137</fpage>
<lpage>158</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182020000100137&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182020000100137&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182020000100137&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Son conocidos los efectos de los anticoagulantes como tratamiento o profilaxis de eventos trombóticos, esto permitió establecer una terapia individualizada según sus necesidades. Se realizó un estudio descriptivo, transversal, no aleatorizado, en 138 pacientes hospitalizados mayores de edad en una institución de cuarto nivel de atención con tratamiento anticoagulante terapéutico y profiláctico, se abordó el tipo de fármaco indicado, periodicidad, efectos adversos, controles de laboratorio, interacciones farmacológicas y causalidad de las reacciones adversas. Se encontró que el anticoagulante con mayor frecuencia de uso fue enoxaparina (68%), el control más utilizado fue el tiempo de protrombina (60,39%), interacciones farmacológicas se identificaron en 47,1%, las más frecuentes con ácido acetil salicílico (29,7% del total de interacciones), las reacciones adversas más frecuentes fueron de índole hematológico (58,3%); y la evaluación de causalidad de reacciones adversas fue 4,2% probable. El estudio mostró que el anticoagulante más utilizado fue enoxaparina. Las interacciones farmacológicas de los anticoagulantes fueron muy frecuentes, especialmente con warfarina. Las reacciones adversas de mayor ocurrencia fueron las de tipo hemorrágico ; y la evaluación de causalidad fue de categoría posible para la mayoría de estas reacciones adversas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY The effects of anticoagulants are known as treatment or prophylaxis of thrombotic events, allowing to establish an individualized therapy according to their needs. A descriptive cross-sectional, non-randomized study was carried out in 138 hospitalized patients of legal age in a fourth-level care institution with therapeutic and prophylactic anticoagulant treatment, addressing the type of drug indicated, periodicity, side effects, laboratory controls, pharmacological interactions and causality of adverse reactions. It was found that the anticoagulant with the highest frequency of use was enoxaparin (68%), the most used control was the prothrombin time (60.39%), pharmacological interactions were identified in 47.1%, being the most frequent with acetylsalicylic acid (29.7% of the total number of interactions), the most frequent adverse reactions were of a hematological nature (58.3%); and the causality assessment of adverse reactions was 4.2% probable. The study showed that the most used anticoagulant was enoxaparin. The pharmacological interactions of anticoagulants were very frequent, especially with warfarin. The most frequent adverse reactions were those of hemorrhagic type; and the causality assessment was of possible category for most of these adverse reactions.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[pacientes hospitalizados]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="es"><![CDATA[warfarina]]></kwd>
<kwd lng="es"><![CDATA[enoxaparina]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[inpatients]]></kwd>
<kwd lng="en"><![CDATA[drug-related side effects and adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[warfarin]]></kwd>
<kwd lng="en"><![CDATA[enoxaparin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaverri]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Yeung]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización farmacoterapéutica de los anticoagulantes orales utilizados en pacientes hospitalizados]]></article-title>
<source><![CDATA[Acta Méd. Costarric]]></source>
<year>2015</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kearon]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[A]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ornelas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blaivas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bounameaux]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Huisman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[S.M]]></given-names>
</name>
<name>
<surname><![CDATA[Vintch]]></surname>
<given-names><![CDATA[J.R.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antithrombotic therapy for VTE disease]]></article-title>
<source><![CDATA[CHEST Journal]]></source>
<year>2016</year>
<volume>149</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>315-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mertens]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Siebenhofer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berghold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices-results of the cluster-randomized PICANT trial (Primary care management for optimized antithrombotic treatment)]]></article-title>
<source><![CDATA[BMC Health Serv. Res]]></source>
<year>2009</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>539</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linkins]]></surname>
<given-names><![CDATA[L.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[P.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[J.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism, a meta-analysis]]></article-title>
<source><![CDATA[Ann. Intern. Med]]></source>
<year>2003</year>
<volume>139</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>893-900</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villines]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fran]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of direct oral anticoagulants, insights from postmarketing studies]]></article-title>
<source><![CDATA[Am. J. Med]]></source>
<year>2016</year>
<volume>129</volume>
<numero>11S</numero>
<issue>11S</issue>
<page-range>S41-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raffo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Masial]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gaete]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vergara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Necrosis cutánea por tratamiento anticoagulante oral]]></article-title>
<source><![CDATA[Caso clínico, Rev. Chil. Cirug]]></source>
<year>2011</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>200-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[Warfarin, enoxaparin, nadroparin, dalteparin, rivaroxabán, dabigatran and fon-daparinux, Micromedex]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seculini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tabares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trombocitopenia inducida por heparina: nuevas opciones terapéuticas]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2016</year>
<volume>76</volume>
<page-range>230-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Licata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puccia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Serruto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Minissale]]></surname>
<given-names><![CDATA[M.G]]></given-names>
</name>
<name>
<surname><![CDATA[Morreale]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Giannitrapani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Soresi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montalto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Almasi]]></surname>
<given-names><![CDATA[P.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases]]></article-title>
<source><![CDATA[Eur. J. Gastroenterol. Hepatol]]></source>
<year>2018</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>226-32</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Le Blanc]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dotterweich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zehe]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Krug]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jakob]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schilling]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schütze]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heparin affects human bone marrow stromal cell fate: Promoting osteogenic and reducing adipogenic differentiation and conversion]]></article-title>
<source><![CDATA[Bone]]></source>
<year>2015</year>
<volume>78</volume>
<page-range>102-13</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding with direct oral anticoagulant vs. warfarin, Clinical experience]]></article-title>
<source><![CDATA[Am. J. Med]]></source>
<year>2016</year>
<volume>129</volume>
<page-range>S33-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidotes for novel oral anticoagulants: Current status and future potential]]></article-title>
<source><![CDATA[Arterioscler. Thromb. Vasc. Biol]]></source>
<year>2015</year>
<volume>35</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1736-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alotaibi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials]]></article-title>
<source><![CDATA[Crit. Rev. Oncol. Hematol]]></source>
<year>2018</year>
<volume>125</volume>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: A meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Arch. Intern. Med]]></source>
<year>2007</year>
<volume>167</volume>
<page-range>1476-86</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[A.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[J.Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>1999</year>
<volume>341</volume>
<page-range>793-800</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leizorovicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[A.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Turpie]]></surname>
<given-names><![CDATA[A.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<page-range>874-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prácticas de prescripción y conocimientos médicos acerca de los anticoagulantes orales directos en un hospital de referencia]]></article-title>
<source><![CDATA[Iatreia]]></source>
<year>2015</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148-56</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dentali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[J.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gianni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis, anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients]]></article-title>
<source><![CDATA[Ann. Intern. Med]]></source>
<year>2007</year>
<volume>146</volume>
<page-range>278-88</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[A.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Tapson]]></surname>
<given-names><![CDATA[V.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Bergmann]]></surname>
<given-names><![CDATA[J.F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational crosssectional study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<numero>387-394</numero>
<issue>387-394</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[II Consenso Colombiano de Tromboembolismo Venoso, Profilaxis en paciente medico agudamente enfermo]]></article-title>
<source><![CDATA[Acta Med. Colomb]]></source>
<year>2005</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>217-21</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de las heparinas de bajo peso molecular (HBPM)]]></article-title>
<source><![CDATA[Emergencias]]></source>
<year>2002</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>38-41</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American. Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)]]></article-title>
<source><![CDATA[J. Am. Coll. Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>970-1062</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertrand]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maarten]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Keith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lars]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur. Heart J]]></source>
<year>2002</year>
<volume>23</volume>
<page-range>1809-40</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Whooley]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Oler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Grady]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1996</year>
<volume>276</volume>
<page-range>811-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heparina no fraccionada en el manejo del síndrome coronario agudo]]></article-title>
<source><![CDATA[Rev. Fac. Med]]></source>
<year>2007</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-57</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Telford]]></surname>
<given-names><![CDATA[A.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1981</year>
<volume>1</volume>
<numero>8232</numero>
<issue>8232</issue>
<page-range>1225-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Theroux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ouimet]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McCans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Latour]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin, heparin, or both to treat acute unstable angina]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>1988</year>
<volume>319</volume>
<page-range>1105-11</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosa]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Burdet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoreo de la terapia con heparina no fraccionada, el APTT tradicional versus la heparinemia por anti-Xa]]></article-title>
<source><![CDATA[Hematología]]></source>
<year>2017</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-92</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Witt]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[N.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaatz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schnurr]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ansell]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism]]></article-title>
<source><![CDATA[J. Thromb. Thrombolysis]]></source>
<year>2016</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-205</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brambatti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Darius]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oldgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial]]></article-title>
<source><![CDATA[Int. J. Cardiol]]></source>
<year>2015</year>
<volume>196</volume>
<page-range>127-31</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[R.G]]></given-names>
</name>
<name>
<surname><![CDATA[Diener]]></surname>
<given-names><![CDATA[H.C]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran the RE-LY trial]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2012</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1511-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J.W]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[S.J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2363-72</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bytzer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RELY trial]]></article-title>
<source><![CDATA[Clin. Gastroenterol. Hepatol]]></source>
<year>2013</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>246-52</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hankey]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2012</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>315-22</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[K.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Wojdyla]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hankey]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial]]></article-title>
<source><![CDATA[Ann. Intern. Med]]></source>
<year>2013</year>
<volume>158</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>861-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherwood]]></surname>
<given-names><![CDATA[M.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Nessel]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Hellkamp]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin, ROCKET AF trial]]></article-title>
<source><![CDATA[J. Am. Coll. Cardiol]]></source>
<year>2015</year>
<volume>66</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2271-81</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[S.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Wojdyla]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Piccini]]></surname>
<given-names><![CDATA[J.P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)]]></article-title>
<source><![CDATA[J. Am. Coll. Cardiol]]></source>
<year>2014</year>
<month>)</month>
<volume>63</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>891-900</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Planes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vochelle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1996</year>
<volume>52</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>47-54</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antman]]></surname>
<given-names><![CDATA[E.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
<name>
<surname><![CDATA[McCAbe]]></surname>
<given-names><![CDATA[C.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>2006</year>
<volume>354</volume>
<page-range>1477-88</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrellier]]></surname>
<given-names><![CDATA[M.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Lebel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Parienti]]></surname>
<given-names><![CDATA[J.-J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short versus extended thromboprophylaxis after total knee arthroplasty: A randomized comparison]]></article-title>
<source><![CDATA[Thrombosis Research]]></source>
<year>2010</year>
<volume>126</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>298-304</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forster]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2016</year>
<volume>3</volume>
<page-range>CD004179</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[A.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[O.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty, The RECORD2 trial]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2007</year>
<volume>110</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>307</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunnelee]]></surname>
<given-names><![CDATA[J.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of an article: Oral rivaroxaban for symptomatic venous thromboembolism]]></article-title>
<source><![CDATA[J. Vasc. Nurs]]></source>
<year>2011</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>89</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[B.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[O.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosencher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial]]></article-title>
<source><![CDATA[Journal of Thrombosis and Haemostasis]]></source>
<year>2007</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2178-85</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="">
<source><![CDATA[RE-MOBILIZE (150 mg) study (2008). Trial-Results Center Clinical Trial Results Database in 100]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[B.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[O.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosencher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>370</volume>
<page-range>949-56</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antman]]></surname>
<given-names><![CDATA[E.M.]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[C.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Gurfinkel]]></surname>
<given-names><![CDATA[E.P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1991</year>
<volume>100</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1593-601</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad y eficacia de enoxaparina en la prevención de enfermedad tromboembólica en pacientes sometidos a cirugía de abdomen]]></article-title>
<source><![CDATA[Cir. Ciruj]]></source>
<year>2002</year>
<volume>70</volume>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whitman-Purves]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Coons]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms]]></article-title>
<source><![CDATA[Clinical and Applied Thrombosis/Hemostasis]]></source>
<year>2018</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>310-6</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[D.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The net clinical benefit of warfarin anticoagulation in atrial fibrillation]]></article-title>
<source><![CDATA[Ann. Intern. Med]]></source>
<year>2009</year>
<volume>151</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>297-305</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romualdi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Donadini]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ageno]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral rivaroxaban after symptomatic venous thromboembolism, the continued treatment study (EINSTEIN-extension study)]]></article-title>
<source><![CDATA[Expert Review of Cardiovascular Therapy]]></source>
<year>2011</year>
<volume>9</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>841-4</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón-Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-Coy]]></surname>
<given-names><![CDATA[E.Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Interacciones farmacológicas entre war-farina y enoxaparina reportadas al programa distrital de farmacovigilancia de Bogotá D.C. 2012-2016]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Ciencias Aplicadas y Ambientales U.D.C.A]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubitza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Becka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Voith]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of enoxaparin on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939, an oral, direct Xa inhibitor]]></article-title>
<source><![CDATA[J. Thromb. Haemost]]></source>
<year>2005</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-04</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubitza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Becka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mueck]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaxoraban, an oral, direct factor Xa inhibitor, has no clinically relevant interaction with acetylsalicylic acid or naproxen]]></article-title>
<source><![CDATA[J. Thromb. Haemost]]></source>
<year>2007</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>659</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidbuchel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Verhamme]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Executive summary]]></article-title>
<source><![CDATA[Eur. Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>2137-49</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ordovás]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Climent]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jover]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales]]></article-title>
<source><![CDATA[Farm. Hosp]]></source>
<year>2009</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>125-33</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[A.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[J.Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>1999</year>
<volume>341</volume>
<page-range>793-800</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[P.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Van Matre]]></surname>
<given-names><![CDATA[E.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[G.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of prophylactic heparin dosage strategies and risk factors for venous thromboembolism in the critically ill patient]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2018</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-41</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Merino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avances en anticoagulación oral, papel del rivaroxaban. Resultados e implicaciones del estudio ROCKET]]></article-title>
<source><![CDATA[Rev. Esp. Cardiol. Supl]]></source>
<year>2013</year>
<volume>13</volume>
<numero>C</numero>
<issue>C</issue>
<page-range>42-6</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gulseth]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nutescu]]></surname>
<given-names><![CDATA[E.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban, an oral direct inhibitor of factor Xa]]></article-title>
<source><![CDATA[Am. J. Health Syst. Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<page-range>1520-9</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escolar]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía sobre los nuevos anticoagulantes orales, Sociedad Española de Hematología y Hemoterapia / Sociedad Española de Trombosis y Hemostasia]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chávez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de reacciones adversas a medicamentos en adultos mayores de 44 años en Bogotá]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2015</year>
<volume>35</volume>
<page-range>34-42</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
